Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLORIA: Olaptesed Pegol in Glioblastoma
NCT04121455Phase 2Active, not recruiting
- Sponsor
- TME Pharma
- Start
- Sep 2019
- Primary completion
- Dec 2028
- Modality
- Polymer-based Nanoparticles, RNA Aptamers, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of olaptesed pegol in glioblastoma (GBM) (11 arms), sponsored by TME Pharma. Primary endpoint: Number of patients with treatment-related adverse events at 3 years. Started Sep 2019; status: active, not recruiting.
02
Drugs
olaptesed pegol
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04121455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04121455.